Clinical trials: Primary Insomnia
Primary Insomnia
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266344
- Testing
- MK0928, gaboxadol / Duration of Treatment 3 Weeks
- Volunteers
- 520 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
A Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Trial name
- NCT00209963
- Testing
- Gaboxadol
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)
The purpose of the study is to test the safety and effectiveness of the Investigational Drug on insomnia.
- Trial name
- NCT00094627
- Testing
- gaboxadol
- Volunteers
- 465 people
- Sponsor
- H. Lundbeck A/S
Sleep Initiation and Maintenance Disorders
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS (NCT00464061)
- Testing
- Volinanserin
- Where
- 22 sites in United States, Argentina and 20 more
- Volunteers
- 1,847 people
- Sponsor
- Sanofi
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097629
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,020 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Disorder, Primary Insomnia
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
SKP-1041 is a new formulation of a marketed sleeping agent called zaleplon. Zaleplon is currently available as Sonata as well as several generic formulations. Sonata and its generics induce sleep soon after ingestion.
- Trial name
- NCT00878553
- Testing
- SKP-1041 (experimental formulation of zaleplon)
- Volunteers
- 67 people
- Sponsor
- Somnus Therapeutics, Inc.
Sleep Initiation and Maintenance Disorders
Efficacy Study of LY2422347 to Treat Insomnia
The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as…
- Trial name
- NCT00259311
- Testing
- LY2422347
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Sleep Initiation and Maintenance Disorders, Insomnia
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with…
- Trial name
- NCT00354809
- Testing
- GW679769
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Insomnia
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.
- Trial name
- NCT00770692
- Testing
- Eszopiclone 1 mg- Elderly, Eszopiclone 2 mg- Elderly, Eszopiclone 3 mg- Non-elderly
- Where
- 34 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Eisai Co., Ltd.
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Primary Insomnia
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266357
- Testing
- MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
- Volunteers
- 50 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia
The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem presentation 5 mg in the induction of sleep in patients with primary insomnia.
- Trial name
- NCT01896336
- Testing
- Zolpidem Hemitartrate
- Where
- Brazil
- Volunteers
- 67 people
- Sponsor
- EMS
Insomnia
Safety and Efficacy Study of APD125 in Patient With Insomnia
The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.
- Trial name
- NCT00452179
- Testing
- APD125
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Arena Pharmaceuticals
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097616
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders, Insomnia
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- GEMS (NCT00253968)
- Testing
- Eplivanserin
- Where
- 12 sites in United States, Argentina and 10 more
- Volunteers
- 967 people
- Sponsor
- Sanofi
Primary Insomnia
Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties
Primary objective: To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake Time After Sleep Onset…
- Trial name
- ECLIPSE (NCT00805350)
- Testing
- Eplivanserin
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 637 people
- Sponsor
- Sanofi
Insomnia
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)
The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.
- Trial name
- NCT00095043
- Testing
- MK0928, gaboxadol
- Volunteers
- 320 people
- Sponsor
- H. Lundbeck A/S
Insomnia Disorder
Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
The main purpose of this study is to evaluate the efficacy and safety of YZJ-1139 in the short-term treatment of primary chronic insomnia, explore the optimal effective dose, and provide the basis for phase III clinical trials
- Trial name
- NCT06680505
- Testing
- YZJ-1139 10mg, YZJ-1139 20mg, YZJ-1139 40mg
- Where
- 33 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Sleep Initiation and Maintenance Disorders, Primary Insomnia
A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients
The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.
- Trial name
- NCT00956319
- Testing
- Zolpidem MR, Estazolam
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Insomnia
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
- Trial name
- NCT00569972
- Testing
- PD 0200390
- Where
- 84 sites in United States, Canada
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Pfizer